\n\n\n\n\t\t\n\t\t\tCorthera\n\t\t\thttp://www.basmedical.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tCorthera, formerly BAS Medical Inc., is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera\u2019s lead product...More»
\n\t\t\tCorthera, formerly BAS Medical Inc., is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera\u2019s lead product candidate, Relaxin, is currently being evaluated in clinical trials for acute heart failure and preeclampsia. Corthera licensed from Connetics Inc. the exclusive, worldwide rights to develop and commercialize Relaxin.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tSan Mateo, CA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\ttherapy,\n\t\t\t\tbilpharmaceutical,\n\t\t\t\tBAS medical,\n\t\t\t\tacute care,\n\t\t\t\trelaxin,\n\t\t\t\tmedical\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series C - $23M (12/2007)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tCaxton Advantage Life Sciences Fund,\n\t\t\t\t\t\n\t\tDomain Associates,\n\t\t\t\t\t\n\t\tKPCB\n\t\t\t\t
\n\t\t\tRecent News
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\tJan 24, 2008\n\t\t\t\t\tCorthera draws $23M for heart-failure drug\n\t\t\t\t
\n\t\t\t\t\n\t\t\t